AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets

AbbVie has joined Anima Biotech’s star-studded roster of partners, paying $42 million upfront to work with the biotech on small molecule mRNA drugs against three “undruggable” targets in oncology and immunology.